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Abstract
Background: It has been suggested that pituitary adenoma results from accumulation of multiple genetic and/or
epigenetic aberrations, which may be identified through association studies. As pituitary tumor transforming gene-
1( PTTG1)/securin plays a critical role in promoting genomic instability in pituitary neoplasia, the present study
explored the association of PTTG1 haplotypes with the risk of pituitary adenoma.
Methods: We genotyped five PTTG1 haplotype-tagging SNPs (htSNP) by PCR-RFLP assays in a case-control study,
which included 280 Han Chinese patients diagnosed with pituitary adenoma and 280 age-, gender- and
geographically matched Han Chinese controls. Haplotypes were reconstructed according to the genotyping data
and linkage disequilibrium status of the htSNPs.
Results: No significant differences in allele and genotype frequencies of the htSNPs were observed between
pituitary adenoma patients and controls, indicating that none of the individual PTTG1 SNPs examined in this study
is associated with the risk of pituitary adenoma. In addition, no significant association was detected between the
reconstructed PTTG1 haplotypes and pituitary adenoma cases or the controls.
Conclusions: Though no significant association was found between PTTG1 haplotypes and the risk of pituitary
adenoma, this is the first report on the association of individual PTTG1 SNPs or PTTG1 haplotypes with the risk of
pituitary adenoma based on a solid study; it will provide an important reference for future studies on the
association between genetic alterations in PTTG1 and the risk of pituitary adenoma or other tumors.
Background
Pituitary tumors are commonly encountered benign
monoclonal adenomas that arise from cells of the anterior
pituitary gland, accounting for approximately 15% of all
diagnosed intracranial tumors [1]. These monoclonal
tumors arise from highly differentiated cells expressing
hormone gene products, including growth hormone, pro-
lactin, adrenocorticotrophic hormone, thyroid-stimulating
hormone, follicle-stimulating hormone and luteinizing
hormone. Pituitary adenomas may be functional and
actively secrete hormones, leading to characteristic clinical
features such as acromegaly, Cushing’s disease and hyper-
prolactinaemia. Commonly, they are non-functional, lead-
ing primarily to hypogonadism and compressive pituitary
failure [1]. Previous longitudinal incidence surveys
reported that the prevalence of pituitary adenoma had
been steadily rising over the last decades [2,3]. A latest epi-
demiological study based on a well-defined population in
the UK reveals that the prevalence of pituitary adenoma is
77.6/100,000, about four-fold higher than previously
thought [4].
Several genetic and epigenetic alterations have been
observed in pituitary tumorigenesis. In addition to clas-
sic cancer genes [5,6], there are a significant number of
genetic or epigenetic alterations in pituitary tumors that
target cell cycle regulators [7]. A completely new
cell cycle pathway involved in pituitary oncogenesis is
represented by pituitary tumor transforming gene-1
(PTTG1)/securin, an oncogenic molecule first identified
in GH4 rat pituitary tumor cells [8]. Playing multiple
roles in cell cycle regulation at different stages, PTTG1
is involved in the mitotic checkpoint that prevents
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any medium, provided the original work is properly cited.abnormal chromosome segregation [7]. It is overexpressed
in a variety of endocrine-related tumors, especially pitui-
tary, thyroid, breast, ovarian, and uterine tumors, as well
as nonendocrine-related cancers in the central nervous,
pulmonary, and gastrointestinal systems [9]. Increased
PTTG1 mRNA expression in pituitary tumor tissue has
been confirmed in several studies [10,11].
While many studies are focused on exploring the
PTTG1-mediated tumorigenic mechanisms, none was
conducted to study the association of genetic alterations in
PTTG1 with the risk of pituitary adenoma. In the present
study, we are the first to have investigated the association
of individual PTTG1 SNPs or PTTG1 haplotypes with the
risk of pituitary adenoma. To comprehensively study the
genetic variants of PTTG1 associated with susceptibility to
pituitary adenomas, we genotyped five PTTG1 haplotype-
tagging SNPs (htSNP) using PCR-RFLP in a case-control
study, which included 280 pairs of age-, gender- and geo-
graphically matched Han Chinese people. The five htSNPs,
including one in the 5’-flanking region, three in the intro-
nic regions, and one in the 3’-flanking region of the
PTTG1 gene, appropriately capture all the common haplo-
type blocks reconstructed in HapMap Phase III data [12].
Methods
Specimens
Blood specimens were collected from 280 Han Chinese
patients diagnosed with pituitary adenoma at Xiangya
Hospital of Central South University between October
2008 and August 2010. None of the patients had
received any treatment before blood sampling. As con-
trols, blood samples were collected from 280 age-, gen-
der- and geographically matched Han Chinese
individuals without a history of tumor at Xiangya Hospi-
tal of Central South University between May and
December, 2007. None of the subjects had a family his-
tory of pituitary adenoma. None of the pituitary ade-
noma patients had a history of familial Cushing’s
syndrome, multiple endocrine neoplasia type 1 (MEN1)
or carney complex. Blood specimens were obtained after
informed consent from all subjects. This study was
approved by the Ethic Committee of Xiangya Hospital.
Tagging SNP Selection
HapMap SNP Phase III data [12] were used to deter-
mine the frequency of SNPs among Han Chinese.
Eighty-four SNPs were obtained from a 17.52-kb region
of PTTG1 from 2 kb upstream of the transcriptional
start site to 4 kb downstream of the 3’ untranslated
region. Tagging SNP selection was done using the Hap-
loview program. The Haploview program implemented
a htSNP selection method proposed by Carlson and col-
leagues, which selects a set of htSNPs such that each
SNP considered has r
2 greater than a prespecified
threshold with at least one of the htSNPs [13]. In our
selection, only SNPs with minor allele frequency greater
than 10% were considered, and the threshold of pairwise
linkage disequilibrium (LD) was set as r
2 = 0.8. A total
of five htSNPs were selected among 84 SNPs considered
across PTTG1,i n c l u d i n go n ei nt h e5 ’-flanking region,
three in the intronic regions, and one in the 3’-flanking
region (Additional file 1).
Genotyping
Genomic DNA from blood specimens was isolated using
standard proteinase K digestion and phenol-chloroform
extraction. The five PTTG1 htSNPs were amplified by
PCR. The sequences of PCR primers are reported in
Additional file 2. The PCR reaction was carried out in a
total volume of 25 μL, containing 50 to 100 ng of geno-
mic DNA, 1 unit of Premix Taq™ DNA polymerase
(Takara, Japan), 0.2 μmol/L of each primer, 1× Ex Taq
Buffer (Mg2+ Plus), 0.25 mmol/L of each deoxynucleo-
tide triphosphate. Genotyping for the htSNPs was done
by RFLP with restriction endonucleases (Additional
file 2). The different alleles were identified on a 4% agar-
ose gel and visualized with ethidium bromide.
Linkage Disequilibrium (LD) and haplotype Analysis
Pairwise measures of LD measured by Lewontin coeffi-
cient (D’) and squared correlation coefficient (r
2)
between the genotyped SNPs were calculated with the
Haploview program [14]. The frequencies of individual
haplotypes were estimated from the genotype data using
the SHEsis program [15], which implement a Full-
Precise-Iteration algorithm for reconstructing haplo-
types. Haplotypes with a frequency less than 0.05 were
not considered in the analysis. Logistic regression analy-
sis was done using SAS PROC LOGISTIC to estimate
the odds ratios (OR) and 95% confidence intervals (95%
CI) of individual SNPs or haplotypes.
Statistical Analysis
Hardy-Weinberg equilibrium analysis for genotype dis-
tribution in controls was carried out by a Chi-square
goodness-of-fit test. Differences in genotype and allele
frequencies between cases and controls were determined
using Chi-square test. Logistic regression was performed
to assess OR and 95% CI. All the statistical analyses
were implemented with SAS 9.1.3. The statistical signifi-
cance level of this study was set at two-sided a = 0.05.
Results
As this was an age- and gender-matched cases-control
study, there was no significant difference in sex and age
between pituitary adenomas patients and controls
(Table 1), and therefore adjustment for age and sex was
not needed in data analysis.
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rs2910201 and rs3811999 were found to depart signifi-
cantly from Hardy-Weinberg equilibrium in controls
and therefore excluded from later analyses. No signifi-
cant difference in allele and genotype frequencies at
any of the remaining three polymorphic sites
(rs1895320, rs2910200, and rs68827420) was observed
between pituitary adenoma patients and controls
(Table 3).
D’ value and r
2 for rs1895320, rs2910200, and
rs6882742 were calculated according to the genotyping
data reported in Table 3. The different degrees of LD
between cases and controls are summarized in Table 4.
LD maps measured by D’ in cases and controls shows
rs2910200 and rs6882742 were in LD with each other
in both cases and controls (D’ > 0.8) (Figure 1). More-
over, rs1895320 and rs2910200 had weaker LD in
cases (D’ =0 . 0 1 2 ,r
2 =0 . 0 )t h a ni nc o n t r o l s( D’ =1 . 0 ,
r
2 =0 . 0 2 6 )( T a b l e4 ;F i g u r e1 ) .A c c o r d i n gt ot h eg e n o -
typing data in pituitary adenoma patients and controls,
2-SNP haplotypes (rs1895320 and rs2910200;
rs2910200 and rs68827420) were reconstructed (Table
5). Haplotypes with frequencies greater than 0.05 were
subject to further analysis. As shown in Table 5, three
2-SNP haplotypes for rs1895320 and rs2910200 or for
rs2910200 and rs6882742 accounted for 100% of the
haplotypes in controls, respectively; the frequencies of
all the 2-SNP haplotypes were not significantly differ-
ent between pituitary adenoma patients and controls.
In addition, no significant association was found
between the 2-SNP haplotypes and histological classifi-
cation of pituitary adenoma (data not shown).
Table 1 Characteristics of Study Samples
Cases (n = 280),
n (%)
Controls (n = 280),
n (%)
P*
Age (mean ± SD) 42.7 ± 13.5 42.3 ± 12.4 0.745
Gender
Male 142 (50.7) 142 (50.7) 1.0
Female 138 (49.3) 138 (49.3)
Histology
CA 34 (12.2)
SA 32 (11.4)
TA 42 (15)
LA 84 (30)
NCA 88 (31.4)
Note: CA, corticotrophic adenoma; SA, somatotrophic adenoma; TA,
thyrotrophic adenoma; LA, lactotrophic adenoma (i.e. prolactinoma); NCA, null
cell adenoma. *Two-sided Chi-square test was applied to Gender and
independent t test was applied to age.
Table 2 Hardy-Weinberg Equilibrium (HWE) Test on
Controls in the Study
Restriction
Enzyme
Reference
SNP ID (rs)
HWE Test P
Value
Chromosome
Position
Minor
Allele
Tsp45 I rs1895320 > 0.05 159782164 C
Bsl I rs2910200 > 0.05 159782569 T
Mbo II rs2910201 < 0.001 159782950 T
Mnl I rs3811999 < 0.001 159779450 T
Bsl I rs6882742 > 0.05 159790342 C
Table 3 Genotype and Allelic Frequencies of PTTG1
htSNPs among Pituitary Adenoma Cases and Controls
and Associations with Risk of Pituitary Adenoma
Cases/Controls OR (95% CI) P
rs1895320
Genotype
CC 2/4 0.46 (0.08-2.57) 0.68
a
CT 84/88 0.91 (0.64-1.31) 0.67
b
TT 194/188 1.00 0.45
c
Allele
C 88/96 0.90 (0.66-1.24)
T 472/464 1.00 0.52*
rs2910200
Genotype
TT 4/4 1.12 (0.27-4.58) 0.73
d
TC 72/54 1.48 (0.99-2.22) 0.06
e
CC 202/222 1.00 1.00
f
Allele
T 80/62 1.35 (0.95-1.93)
C 476/498 1 0.10*
rs6882742
Genotype
CC 4/10 0.36 (0.11-1.16) 0.27
g
CT 90/104 0.80 (0.56-1.14) 0.26
h
TT 176/166 1.00 0.11
i
Allele
C 98/124 0.78 (0.58-1.05)
T 442/436 1.00 0.10*
Note: As certain genotypes have expected count less than 5 in cases or
controls, separate Fisher’s exact tests and Chi-square tests are performed
where appropriate. a, Fisher’s exact P value for rs1895320 CC vs. CT; b, Chi-
square P value for rs1895320 CT vs. TT; c, Fisher’s exact P value for rs1895320
CC vs. TT; d, Fisher’s exact P value for rs2910200 TT vs. TC; e, Chi-square P
value for rs2910200 TC vs. CC; f, Fisher’s exact P value for rs2910200 TT vs. CC;
g, Fisher’s exact P value for rs6882742 CC vs. CT; h, Chi-square P value for
rs6882742 CT vs. TT; i, Fisher’s exact P value for rs6882742 CC vs. TT; *Chi-
square P value.
Table 4 D’ and r
2 between Pairs of Three PTTG1 htSNPs
in Pituitary Adenoma Cases and Controls
htSNP Pairs D’ Cases/Controls r
2 Cases/Controls
rs1895320 rs2910200 0.012/1.000 0.000/0.026
rs1895320 rs6882742 0.595/0.764 0.303/0.425
rs2910200 rs6882742 0.999/1.000 0.038/0.035
Note: Values of D’ and r
2 were calculated with the Haploview program.
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Pituitary tumors are common intracranial neoplasms
that cause significant morbidity through mass effects
and/or inappropriate secretion of pituitary hormones
[16]. The prevalence of pituitary adenoma has dramati-
cally increased in the past decade [4].
PTTG1/securin is a vital component of the spindle
checkpoint controlling faithful chromatid separation. It
inhibits separase, the major effector for chromosome
segregation during mitosis [17]. Overexpression of
PTTG1 causes cell transformation and induces aneu-
ploidy [18,19], whereas either abundance or loss of it
can lead to dysregulated G2/M checkpoint surveillance,
resulting in abnormal mitosis and chromosomal instabil-
ity. Absence of this gene results in a decrease in the
incidence of pituitary tumors in pRB heterozygous mice,
probably by triggering ARF/p53/p21-dependent senes-
cence [20,21]. In contrast, overexpression PTTG1 in the
pituitary in transgenic mice leads to pituitary hyperplasia
and focal microadenomas [22]. All the previous findings
indicate that PTTG1 is required for pituitary tumorigen-
esis, which warrant our study to explore possible asso-
ciation of genetic alterations in PTTG1 with the risk of
pituitary adenoma, using htSNP and haplotype analyses
to comprehensively capture various genetic variants of
PTTG1 in a Han Chinese population. However, our
results revealed no significant association between indi-
vidual PTTG1 htSNPs or reconstructed PTTG1 haplo-
types and the risk of pituitary adenoma, suggesting that
genetic variation in PTTG1 is not an imporant contri-
buting factor to pituitary tumorigenesis. PTTG1 seems
to promote pituitary tumor formation through a variety
of other ways.
Zhang et al. reported that PTTG1 mRNA was overex-
pressed in more than 90% of all types of pituitary
tumors [10]. Based on our results, it seems that the
PTTG1 mRNA overexpression in pituitary adenoma is
more likely through epigenetic mechanisms rather than
variation in the DNA sequence of PTTG1.H o l te ta l .
reported that PTTG1 was regulated by cyclin-dependent
kinase (CDK)-mediated phosphorylation [23], suggesting
a link between the control of the cell cycle by CDKs
Figure 1 LD Maps of Three htSNPs in Pituitary Adenoma Cases
and Controls. The Value in each diamond is measured as D’
corresponding to the dark gray-to-white color gradient. Dark gray
diamonds without a number indicate that the value of D’ was 1.
Table 5 Frequencies of Estimated 2-SNP Haplotypes of PTTG1 in Pituitary Adenoma Cases and Controls
rs1895320 – rs2910200 2-SNP Haplotype rs2910200 – rs6882742 2-SNP Haplotype
CC TT TC CC TT CT
Cases (%)/Controls (%) 13.4/17.1 12.0/11.1 72.2/71.8 18.2/22.1 14.5/11.1 67.2/66.8
OR
(95% CI)*
0.77
(0.56-1.07)
1.13
(0.78-1.63)
1.12
(0.86-1.46)
0.78
(0.58-1.06)
1.36
(0.95-1.95)
1.02
(0.79-1.32)
P 0.120 0.532 0.416 0.107 0.089 0.865
Note: Haplotypes with frequencies > 5% were included. *Calculated with the SHEsis program.
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growth factor, c-myc and cyclin D3 to enhance cell pro-
liferation [24-26], and interacts with Ku and p53 to par-
ticipate in DNA damage/repair and apoptosis [27].
Interplay between PTTG1 and the cell signaling mole-
cules, rather than DNA sequence variation in the
PTTG1 gene, may actually play an important role in
pituitary tumorigenesis. Nevertheless, individual SNP
analysis and/or haplotype analysis on genes of the inter-
action partners of PTTG1, or on newly identified candi-
date genes involved in pathogenesis of pituitary
adenoma, such as the bone morphogenetic protein-4
(BMP-4) gene and the RWD-containing sumoylation
enhancer (RSUME) gene [28], may yield interesting
results.
Conclusions
Though no significant association was found between
PTTG1 haplotypes and the risk of pituitary adenoma,
this is the first report on the association of individual
PTTG1 SNPs or PTTG1 haplotypes with the risk of
pituitary adenoma based on a solid study; it will provide
an important reference for future studies on the associa-
tion between genetic alterations in PTTG1 and the risk
of pituitary adenoma or other tumors.
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